# Evaluating the Safety and Efficacy of the Probiotic Bifidobacterium Longum ES1 and the Post Biotic Heat-treated Bifidobacterium Longum ES1 (HT-ES1) on IBS Symptom Severity in Patients With Diarrhoea Predominant Irritable Bowel Syndrome

> **NCT05339243** · NA · COMPLETED · sponsor: **Vedic Lifesciences Pvt. Ltd.** · enrollment: 200 (actual)

## Conditions studied

- Irritable Bowel Syndrome With Diarrhea

## Interventions

- **OTHER:** ES 1
- **OTHER:** HT ES1
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT05339243
- **Lead sponsor:** Vedic Lifesciences Pvt. Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-04-21
- **Primary completion:** 2023-01-13
- **Final completion:** 2023-01-13
- **Target enrollment:** 200 (ACTUAL)
- **Last updated:** 2023-09-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05339243

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05339243, "Evaluating the Safety and Efficacy of the Probiotic Bifidobacterium Longum ES1 and the Post Biotic Heat-treated Bifidobacterium Longum ES1 (HT-ES1) on IBS Symptom Severity in Patients With Diarrhoea Predominant Irritable Bowel Syndrome". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT05339243. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*